ID: ALA4527301

Max Phase: Preclinical

Molecular Formula: C23H16ClFN4O2

Molecular Weight: 434.86

Molecule Type: Unknown

Representations

Canonical SMILES:  Fc1cccc(COc2ccc(Nc3nccc4[nH]c(-c5ccco5)nc34)cc2Cl)c1

Standard InChI:  InChI=1S/C23H16ClFN4O2/c24-17-12-16(6-7-19(17)31-13-14-3-1-4-15(25)11-14)27-23-21-18(8-9-26-23)28-22(29-21)20-5-2-10-30-20/h1-12H,13H2,(H,26,27)(H,28,29)

Standard InChI Key:  NSNAENYGIMVJTA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 434.86

Molecular Weight (Monoisotopic): 434.0946

AlogP: 6.33

#Rotatable Bonds: 6

Polar Surface Area: 75.97

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 8.05

CX Basic pKa: 6.01

CX LogP: 5.47

CX LogD: 5.38

Aromatic Rings: 5

Heavy Atoms: 31

QED Weighted: 0.33

Np Likeness Score: -1.75

References

1. Gavriil ES, Doukatas A, Karampelas T, Myrianthopoulos V, Dimitrakis S, Mikros E, Marakos P, Tamvakopoulos C, Pouli N..  (2019)  Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy.,  176  [PMID:31125894] [10.1016/j.ejmech.2019.05.029]

Source

Source(1):

• Scientific Literature